Skip to main content
. Author manuscript; available in PMC: 2016 Apr 12.
Published in final edited form as: Bone Marrow Transplant. 2009 Dec 7;45(7):1212–1219. doi: 10.1038/bmt.2009.329

Figure 3. Kaplan Meier estimate of the cumulative incidence of HCMV DNAemia according to Campath in vivo use.

Figure 3

The cumulative incidence of HCMV DNAemia in the group receiving no Campath in vivo (red line, n=85) was 42.8 ± 5.8 %, for the group receiving Campath-1G in vivo (blue line, n=28) was 41.6 ± 10.4 %, and for the group receiving Campath-1H (green line, n=32) was 64.7 ± 8.6 %. The difference in the cumulative incidence of DNAemia between the Campath-1H group and the no Campath group was significant (p = 0.002, Log Rank Score), while the difference between the group receiving Campath-1G and no Campath group (p = 0.71, Log Rank Score), and Campath-1G and Campath-1H (p = 0.13, Log Rank Score) was not significant. The cross bars indicate censored data.